Additive Effects of Pravastatin and Valsartan

Phase 4

Completed

• Conditions: Hypertension; High Cholesterol
• Interventions: Drug: pravastatin, valsartan, pravastatin+valsartan

• Registration Number: NCT01004237
• Lead Sponsor: Gachon University Gil Medical Center

Brief Summary

The investigators hypothesize that pravastatin combined with valsartan may have additive effects in hypertensive, hypercholesterolemic patients.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2009-10-28
• Study First Submitted QC: 2009-10-28
• Study First Posted: 2009-10-29
• Study Start: 2009-11
• Status Verified: 2010-10
• Primary Completion: 2012-04
• Study Completion: 2012-04
• Last Update Submitted: 2012-08-08
• Last Update Posted: 2012-08-09

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 52

Inclusion Criteria

• Hypertension and low-density lipoprotein cholesterol levels >100

Exclusion Criteria

• Overt liver disease Chronic renal failure Hypothyroidism Myopathy Uncontrolled diabetes Severe hypertension

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: CROSSOVER

Arm && Interventions

Group	Intervention	Description
pravastatin	pravastatin, valsartan, pravastatin+valsartan	-
valsartan	pravastatin, valsartan, pravastatin+valsartan	-
pravastatin combined with valsartan	pravastatin, valsartan, pravastatin+valsartan	-

Primary Outcome Measures

Name	Time	Method
flow-mediated dilation	8 weeks of treatment

Secondary Outcome Measures

Name	Time	Method
insulin resistance	8 weeks of treatment

Trial Locations

Locations (1)

Gil Medical Center; 🇰🇷 Incheon, Korea, Republic of